There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues.
Buy your copy of this report @ http://www.reportsnreports.com/reports/190914-pharmaceutical-products-of-the-future-50-company-biopharma-and-traditional-pipeline-analysis-to-2016.html
Report Details:
Published: August 2012
No. of Pages: 220
Price:Single User License:US$2500 Corporate User License:US$5000
Coverage of the 50 Leading Companies
This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:
Abbott Laboratories
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen IDEC
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly & Co.
Forest
Gilead Sciences
GlaxoSmithKline
Grifols SA
Hospira
Johnson & Johnson
Kyowa Kirin
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Reckitt Benckiser
Roche
Sanofi
Santen Pharmaceuticals
Servier
Shionogi
Shire
Taisho Pharmacueitcal
Takeda
TEVA
UCB
Valeant Pharmaceuticals
Warner Chilcott
Watson
While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.
Pipeline Analysis, Key Trends, Market Forecasts
This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.
As part of its coverage, the report provides the following:
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
The Traditional Pharmaceutical Market
Biotechnology Market Facts and Forecast
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.
The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.
Issues and Trends discussed in this report include:
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry
Buy your copy of this report @ http://www.reportsnreports.com/reports/190914-pharmaceutical-products-of-the-future-50-company-biopharma-and-traditional-pipeline-analysis-to-2016.html
Report Details:
Published: August 2012
No. of Pages: 220
Price:Single User License:US$2500 Corporate User License:US$5000
Coverage of the 50 Leading Companies
This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:
Abbott Laboratories
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen IDEC
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corp.
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly & Co.
Forest
Gilead Sciences
GlaxoSmithKline
Grifols SA
Hospira
Johnson & Johnson
Kyowa Kirin
Lundbeck
Menarini
Merck
Merck KGaA
Mitsubishi Tanabe Pharma
Mylan
Novartis
Novo Nordisk
Ono Pharmaceutical Co.
Otsuka Pharmaceutical
Pfizer
Purdue Pharma
Reckitt Benckiser
Roche
Sanofi
Santen Pharmaceuticals
Servier
Shionogi
Shire
Taisho Pharmacueitcal
Takeda
TEVA
UCB
Valeant Pharmaceuticals
Warner Chilcott
Watson
While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.
Pipeline Analysis, Key Trends, Market Forecasts
This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.
As part of its coverage, the report provides the following:
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
The Traditional Pharmaceutical Market
Biotechnology Market Facts and Forecast
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.
The industry has struggled in recent years but many observers see biopharmaceutical as the key to continued success for market leaders. Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses. The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.
Issues and Trends discussed in this report include:
Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Biosimilar Development
Aging Populations
Mergers, Acquisitions, and Collaborations
Contributors to R&D Success
R&D Spending Trends
The Role of Contract Research Organizations
Sustainability in a Changing Pharmaceutical Industry
